A detailed history of Bank Of Montreal transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Bank Of Montreal holds 5,980 shares of PTGX stock, worth $272,269. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,980
Holding current value
$272,269
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $201,645 - $283,033
5,980 New
5,980 $268,000
Q2 2023

Aug 02, 2023

BUY
$18.02 - $29.36 $5.59 Million - $9.1 Million
310,000 New
310,000 $8.56 Million
Q1 2022

May 12, 2022

SELL
$23.34 - $36.08 $499,476 - $772,112
-21,400 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$17.63 - $37.1 $7,140 - $15,025
-405 Reduced 1.86%
21,400 $734,000
Q3 2021

Nov 12, 2021

SELL
$12.95 - $49.69 $550,051 - $2.11 Million
-42,475 Reduced 66.08%
21,805 $385,000
Q2 2021

Aug 12, 2021

BUY
$25.57 - $44.88 $1.64 Million - $2.88 Million
64,280 New
64,280 $2.84 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.23B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.